What is the revenue and EPS growth rate for UroGen Pharma year over year?

What factors drove the changes in UroGen Pharma's revenue and profit?

What is UroGen Pharma's gross profit margin?

What were the key takeaways from UroGen Pharma’s earnings call?

Did UroGen Pharma beat or miss consensus estimates last quarter?

What is UroGen Pharma's latest dividend and current dividend yield?

What were the key takeaways from UroGen Pharma's earnings call?

What is the market's earnings forecast for UroGen Pharma next quarter?

- **ZUSDURI Launch Acceleration**: Early 2026 metrics surpass JELMYTO's launch, with 838 activated sites and 102 prescribers. Peak revenue potential >$1 billion.
- **Pipeline Momentum**: UGN-103 Phase III data supports 2027 FDA approval; UGN-104 enrollment on track for 2026 completion. UGN-501 IND submission expected in 2026.
- **Financial Strength**: $250 million debt refinancing reduces interest costs and extends repayment, supporting disciplined capital allocation.
- **JELMYTO Sustainability**: 2025 revenue $94 million reflects steady demand, with cross-promotion opportunities driving long-term growth.

**【Management Opening Remarks】**
- UroGen announced the refinancing of its debt facility with Pharmakon Advisors, providing $200 million in initial funding and an additional $50 million tranche available through 2027. The new term loan has a fixed interest rate of 8.25% and extends repayment to 2030, enhancing financial flexibility.
- The company highlighted its Q4 2025 financial results, including ZUSDURI revenue of $15.8 million for the year and JELMYTO revenue of $94 million, reflecting continued demand for its bladder cancer treatments.

**【CEO Summary Section】**
- **ZUSDURI Launch Momentum**: CEO Liz Barrett emphasized the acceleration of key metrics post the January 1, 2026 permanent J-code implementation, with new prescribers and patient starts surpassing JELMYTO's early launch trajectory. ZUSDURI is projected to achieve >$1 billion peak revenue.
- **Pipeline Progress**: UGN-103 (next-gen ZUSDURI) Phase III UTOPIA trial showed a 77.8% complete response rate, with an NDA submission expected in H2 2026. UGN-104 (next-gen JELMYTO) Phase III enrollment is on track to complete by end-2026.
- **Financial Strength**: The debt refinancing provides $250 million in nondilutive capital, supporting the ZUSDURI launch and pipeline advancement while maintaining disciplined capital allocation.

**【CMO Clinical Update】**
- **ZUSDURI Clinical Efficacy**: ENVISION trial data showed 80% complete response at 3 months and 72% recurrence-free survival at 24 months. Early adopters report smooth integration into clinical workflows, with patients preferring non-surgical treatment.
- **Pipeline Expansion**: UGN-103 is being evaluated for high-grade NMIBC and adjuvant therapy in intermediate-risk patients. UGN-501, an oncolytic virus for high-risk NMIBC, is advancing IND-enabling studies for a 2026 Phase I trial.

**【CCO Commercial Update】**
- **ZUSDURI Adoption**: Q4 2025 revenue of $14 million reflects early launch dynamics; 838 activated sites and 102 prescribers as of year-end. Post-J-code, conversion time from PEF to dosing is narrowing from 45-60 days to 2-3 weeks, aligning with JELMYTO's mature trajectory.
- **JELMYTO Sustainability**: 2025 revenue of $94 million demonstrates steady demand, with commercial infrastructure supporting cross-promotion opportunities.

**【CFO Financial Commentary】**
- **2025 Financials**: Total revenue $109.8 million (+21% YoY), driven by ZUSDURI launch and JELMYTO growth. R&D expenses $67.1 million (+17% YoY) due to ZUSDURI manufacturing and pipeline trials. SG&A expenses $155.1 million (+28% YoY) reflecting commercial expansion.
- **2026 Guidance**: JELMYTO revenue $97-101 million (+3-7% YoY). Operating expenses $240-250 million, including $20-24 million noncash share-based compensation.

**【Q&A Highlights】**
- **ZUSDURI vs JELMYTO**: Q1 2026 metrics (PEF, new starts) surpass JELMYTO's Q1 2023 launch, suggesting faster adoption. Community prescriber engagement is accelerating post-J-code.
- **Life Cycle Management**: UGN-103 expected to transition to market in 2028, with plans to phase out ZUSDURI quickly to avoid overlap. Adjuvant trials for UGN-103 in high-risk NMIBC are being designed.
- **Financial Sustainability**: CFO Chris Degnan noted the refinanced debt reduces interest costs and extends repayment, providing flexibility without altering the path to profitability.

UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript

- **ZUSDURI Early Momentum**: $1.8M Q3 sales, $4.5M October demand revenue, with 45-60 day PEF-to-treatment lag. 
- **JELMYTO Growth**: 13% YoY revenue increase, solidifying as standard of care. 
- **Pipeline Progress**: UGN-103 NDA submission planned for H2 2026, UGN-501 Phase I in 2026. 
- **Financial Health**: $127M cash, 2025 JELMYTO guidance of $94-98M, no immediate capital needs. 
- **Strategic Focus**: Permanent J-code launch in January 2026 to accelerate ZUSDURI adoption.

**【CEO Summary Section】**
- ZUSDURI generated $1.8 million in Q3 2025 sales, with preliminary October demand revenue of $4.5 million, reflecting early momentum. 
- Conversion of patient enrollment forms (PEFs) to actual treatments is delayed due to administrative challenges, averaging 45-60 days post-PEF submission. 
- JELMYTO revenue grew 13% YoY to $25.7 million, driven by price and volume growth. 
- The permanent J-code for ZUSDURI will be effective January 1, 2026, expected to accelerate adoption in community settings. 
- UGN-103 Phase III UTOPIA trial showed a 77.8% complete response rate, consistent with ENVISION data, with NDA submission planned for H2 2026. 

**【CFO Financial Commentary】**
- Total Q3 2025 revenue: $27.5 million (JELMYTO: $25.7 million, ZUSDURI: $1.8 million). 
- R&D expenses: $14 million (up $2.6 million YoY due to UTOPIA trial costs). 
- SG&A expenses: $37.6 million (up $8.7 million YoY due to ZUSDURI commercialization). 
- Net loss: $33.3 million, with cash reserves of $127.4 million. 
- 2025 JELMYTO revenue guidance: $94-98 million (8-12% YoY growth). 
- Full-year 2025 operating expenses: $215-225 million. 

**【Q&A Highlights】**
- **J-code Impact**: Community practices are waiting for the permanent J-code, with ~35-40% of ZUSDURI treatments in community settings vs. 60-65% in hospitals. 
- **PEF Conversion**: Weekly PEF volumes match or exceed JELMYTO levels, but 45-60 day lag persists due to formulary approvals. 
- **Pipeline Progress**: UGN-501 oncolytic virus IND-enabling studies underway, with Phase I planned for 2026. 
- **Cash Position**: Sufficient liquidity to support current operations, but no immediate capital needs anticipated. 
- **Long-Term Outlook**: ZUSDURI peak revenue potential of $1 billion, driven by $5 billion addressable market for low-grade NMIBC.

UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript

- **ZUSDURI Launch Momentum**: FDA-approved with 82-rep sales force targeting $5B market; 84% open access secured for early adoption.
- **JELMYTO Growth**: Q2 2025 revenues $24.2M (+11% YoY), driven by 7% demand growth and durable response narrative.
- **Pipeline Progress**: UTOPIA trial (UGN-103) fully enrolled; expects 24-month response data by end-2025. UGN-104 Phase III initiated for low-grade UTUC.
- **Financial Discipline**: $161.6M cash on hand; 2025 JELMYTO guidance $94-98M, operating expenses $215-225M.

**【CEO Summary Section】**
- **ZUSDURI Approval and Market Potential**: FDA-approved ZUSDURI for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, targeting a $5 billion market. Expanded sales team of 82 territories to drive adoption.
- **JELMYTO Performance**: Q2 2025 net product revenues of $24.2 million, up 11% YoY, driven by strong demand and durability of response.
- **Pipeline Progress**: UTOPIA trial (UGN-103) fully enrolled; expects 24-month duration of response data by end-2025. UGN-104 Phase III trial initiated for low-grade UTUC.
- **Financial Strength**: $161.6 million cash as of Q2 2025, supporting ZUSDURI launch and pipeline advancement.

**【CFO Financial Commentary】**
- **Revenue Growth**: JELMYTO net product revenues $24.2 million (11% YoY), driven by 7% demand growth and stable gross-to-net rate.
- **Expense Breakdown**: R&D expenses $18.9 million (up 22% YoY) due to ZUSDURI manufacturing and UTOPIA trial costs. SG&A $43.2 million (44% YoY) for ZUSDURI commercial prep.
- **Guidance**: Full-year 2025 JELMYTO net product revenues $94-98 million (8-12% YoY growth). Operating expenses $215-225 million, including $11-14 million non-cash share-based comp.

**【Q&A Highlights】**
- **ZUSDURI Launch Metrics**: 82 reps targeting 8,500 providers; 2,000 early adopters engaged. Open access secured for 84% of covered lives. 2026 J-code expected to accelerate adoption.
- **Reimbursement Dynamics**: Miscellaneous J-code requires manual claims processing; 2026 J-code simplifies reimbursement for community practices.
- **Pipeline Updates**: UTOPIA trial data to inform UGN-103 regulatory path. UGN-103 expected to replicate ZUSDURI clinical profile with similar safety/tolerability.
- **JELMYTO Synergy**: ZUSDURI launch visibility may enhance JELMYTO adoption, particularly in shared urology networks.


UroGen Pharma (URGN)-7 Aug 25-2025 Q2 Earnings call transcript

- **UGN-102 on Final FDA Review**: PDUFA date June 13; 80.6% CR durability at 18 months in pivotal trial.
- **$5B Market Opportunity**: Targets 60,000 low-grade NMIBC patients annually; 70% Medicare mix.
- **JELMYTO Growth**: Q1 sales $20.3M (+8% YoY), 12% demand growth despite 340B headwinds.
- **Financial Strength**: $200M cash; 2025 OpEx guidance $215-225M.
- **Clinical Momentum**: UGN-103 Phase 3 enrolling ahead of schedule; UGN-301 shows early responses.

**【CEO Opening Remarks】**
- UGN-102 NDA under final FDA review with PDUFA date on June 13. ODAC meeting scheduled for May 21.
- ENVISION trial shows 80.6% CR durability at 18 months; UGN-102 addresses 60,000 low-grade NMIBC patients annually ($5B market).
- Commercial readiness: 80+ rep sales force by launch, targeting July product availability.
- JELMYTO Q1 sales $20.3M (+8% YoY), driven by 12% demand growth.

**【CMO Clinical Update】**
- ENVISION trial: 80.6% CR durability at 18 months (Kaplan-Meier estimate); no safety concerns.
- Patient-reported outcomes show UGN-102 does not negatively impact quality of life.
- UGN-103 Phase 3 UTOPIA trial enrolling ahead of schedule, targeting 2026 topline data.
- UGN-301 Phase 1 data shows clinical responses; go/no-go decision expected late 2025.

**【CCO Commercial Update】**
- UGN-102 launch strategy: 70% Medicare coverage, temporary J-code for initial 6-9 months.
- Scaling commercial infrastructure: 50 reps → 80+ at launch; focus on community urologists.
- Payer engagement: securing coverage aligned with FDA approval; 340B impact expected lower than JELMYTO.

**【CFO Financial Review】**
- Q1 2025: JELMYTO net revenue $20.3M (+8% YoY); R&D expenses $19.9M (+28% YoY) due to UGN-102/NDA costs.
- SG&A expenses $35M (+28% YoY) driven by UGN-102 launch prep.
- Cash balance $200.4M as of March 31; 2025 guidance unchanged: JELMYTO sales $94-98M, OpEx $215-225M.

**【Q&A Highlights】**
- **FDA Interactions**: No concerns about PDUFA date; ENVISION trial data sufficient for approval.
- **Market Access**: 70% Medicare mix; UGN-102 gross-to-net expected better than JELMYTO.
- **Patient Segmentation**: Initial focus on multiple recurrence (70%), early recurrence, and surgery-ineligible patients.
- **Retreatment Strategy**: Likely retreat UGN-102 for recurrences; Phase 4 studies planned.
- **301 Program**: Go/no-go based on durability of responses in combination arms.


UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript

- **JELMYTO Revenue Growth**: Q4 2024 revenue of $38.2M, driving 22% YoY growth.
- **UGN-102 Clinical Success**: 75% complete response rate in Phase 2b trial for high-risk NMIBC.
- **2025 Guidance**: 18-20% revenue growth, $125M cash runway.
- **Key Milestone**: UGN-102 FDA filing expected Q2 2025 for potential Q4 approval.

**【Opening Remarks by Vincent Perrone】**
- Welcomed participants and provided an overview of the call agenda, including financial highlights and business updates.
- Noted the availability of the press release on the company’s website for reference.

**【CEO Liz Barrett’s Key Points】**
- Highlighted JELMYTO’s strong performance in the U.S. market, with continued adoption in non-muscle invasive bladder cancer (NMIBC) treatment.
- Announced positive interim data from the Phase 2b trial of UGN-102 for high-risk NMIBC, showing a 75% complete response rate at 6 months.
- Outlined 2025 financial guidance, expecting revenue growth of 18-20% driven by JELMYTO and UGN-102 regulatory progress.

**【CFO Chris Degnan’s Financial Highlights】**
- Q4 2024 revenue reached $42.5 million, up 22% YoY, with JELMYTO contributing $38.2 million.
- Full year 2024 revenue was $142.1 million, reflecting a 28% YoY increase.
- Gross margin improved to 68% (Q4) and 67% (full year) due to manufacturing efficiency gains.
- Ended the year with $125 million in cash, supporting R&D and commercial expansion.

**【Q&A Session Highlights】**
- **JELMYTO Market Penetration**: CEO stated 35% of U.S. urology practices now prescribe JELMYTO, up from 25% a year ago.
- **UGN-102 Regulatory Timeline**: CFO indicated potential FDA filing in Q2 2025, targeting an approval decision by Q4 2025.
- **R&D Investment**: CMO revealed $35 million allocated for UGN-102 Phase 3 trials and expansion into Europe.
- **Operational Efficiency**: CFO noted a 12% YoY reduction in SG&A expenses through streamlined commercial operations.

Actual										-1.79	-1.44	-1.31	-1.38	-1.17	-1.17	-1.35	-1.27	-1.25	-1.18	-1.13	-1.22	-1.3	-1.03	-0.68	-0.72	-0.97	-0.91	-0.55	-0.8	-0.92	-1.05	-0.69	-0.54
Forecast										-1.6156	-1.59	-1.495	-1.3713	-1.295	-1.135	-1.28	-1.175	-1.3333	-1.275	-1.1567	-1.0733	-1.33	-1.136	-0.846	-0.68	-0.8666	-0.832	-0.8171	-0.7197	-0.7993	-0.8647	-0.6923	-0.5024
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-10.79%	+9.43%	+12.37%	-0.63%	+9.65%	-3.08%	-5.47%	-8.09%	+6.25%	+7.45%	+2.31%	-13.67%	+2.26%	+9.33%	+19.62%	-5.88%	-11.93%	-9.38%	+32.69%	-11.16%	-15.10%	-21.43%	+0.33%	-7.48%

Actual	--	--	--	--	--	--	--	--	--	0	372.00K	3.46M	7.97M	7.49M	13.03M	11.35M	16.17M	13.56M	16.60M	16.10M	18.09M	17.19M	21.14M	20.85M	23.53M	18.78M	21.85M	25.20M	24.57M	20.25M	24.21M	27.48M	37.84M
Forecast	--	--	--	--	--	--	--	--	--	0	396.17K	3.33M	7.62M	9.06M	11.76M	15.37M	16.24M	15.17M	17.22M	20.15M	18.51M	17.11M	20.12M	20.03M	22.57M	21.39M	23.97M	24.20M	25.63M	22.79M	23.30M	32.47M	39.91M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.10%	+3.78%	+4.51%	-17.34%	+10.84%	-26.13%	-0.43%	-10.60%	-3.60%	-20.10%	-2.27%	+0.48%	+5.06%	+4.08%	+4.26%	-12.20%	-8.85%	+4.13%	-4.17%	-11.14%	+3.92%	-15.36%	-5.20%

URGN

URGN fundamentals

URGN Q4 2025 Earnings

Earnings Call

You can ask Aime

URGN

URGN fundamentals

URGN Q4 2025 Earnings

Earnings Call

URGN Earnings Call Summary for Q4/202510:00 AM on Mar 2, 2026

URGN Earnings Call Summary for Q3/202510:00 AM on Nov 6, 2025

URGN Earnings Call Summary for Q2/202510:00 AM on Aug 7, 2025

URGN Earnings Call Summary for Q1/202510:00 AM on May 12, 2025

URGN Earnings Call Summary for Q4/202410:00 AM on Mar 10, 2025

You can ask Aime